Nanexa AB (publ) (STO:NANEXA)

Market Cap	579.34M +223.4%
Revenue (ttm)	55.94M +19.8%
Net Income	-11.39M
EPS	-0.07
Shares Out	164.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	829,104
Average Volume	553,704
Open	3.605
Previous Close	3.520
Day's Range	3.600 - 3.945
52-Week Range	0.701 - 5.000
Beta	2.01
RSI	39.52
Earnings Date	Mar 26, 2026

About Nanexa AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 15
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NANEXA

Financial Performance

In 2025, Nanexa AB's revenue was 55.94 million, an increase of 19.80% compared to the previous year's 46.69 million. Losses were -11.39 million, -54.27% less than in 2024.